Gene:
SKI
v-ski sarcoma viral oncogene homolog (avian)

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB contains no drug labels with pharmacogenomic information for this . To report a drug label with PGx, click here.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

Overview

Alternate Names:  None
Alternate Symbols:  None
PharmGKB Accession Id: PA35796

Details

Cytogenetic Location: chr1 : p36.33 - p36.33
GP mRNA Boundary: chr1 : 2160134 - 2241652
GP Gene Boundary: chr1 : 2150134 - 2244652
Strand: plus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

PharmGKB contains no curated pathways for this gene. If you would like to volunteer to work on a pathway, please let us know.

External Pathways

Links to non-PharmGKB pathways.

  1. BMP receptor signaling - (Pathway Interaction Database NCI-Nature Curated)
  2. Regulation of nuclear SMAD2/3 signaling - (Pathway Interaction Database NCI-Nature Curated)
  3. Signaling by TGF beta - (Reactome via Pathway Interaction Database)
  4. Signaling by BMP - (Reactome via Pathway Interaction Database)
  5. Signaling by TGF beta - (Reactome via Pathway Interaction Database)

LinkOuts

Entrez Gene:
6497
OMIM:
164780
UCSC Genome Browser:
NM_003036
RefSeq RNA:
NM_003036
RefSeq Protein:
NP_003027
RefSeq DNA:
AC_000044
AC_000133
NC_000001
NG_013084
NT_004350
NW_001838585
NW_921350
UniProtKB:
SKI_HUMAN (P12755)
Ensembl:
ENSG00000157933
GenAtlas:
SKI
GeneCard:
SKI
MutDB:
SKI
ALFRED:
LO041699D
HuGE:
SKI
Comparative Toxicogenomics Database:
6497
ModBase:
P12755
HumanCyc Gene:
HS08255
HGNC:
10896

Common Searches